Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Olmos

Showing results (11-20 of 130) with videos related to

Pageof 13
Sort By:
Cancer Research|June 11, 2009
Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone drivenGerhardt Attard, Alison H M Reid, David Olmos, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 1, 2005
Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitisAntonio Rueda Domínguez, David Olmos Hidalgo, Ruth Viciana Garrido, et al.
Expert Opinion on Investigational Drugs|July 23, 2011
Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategiesTimothy A Yap, David Olmos, Lulama Rhoda Molife, et al.
Cancer Journal (Sudbury, Mass.)|June 8, 2010
Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedsideDavid Olmos, Daniel S W Tan, Robin L Jones, et al.
Cancers|March 16, 2019
BRCA2 and Other DDR Genes in Prostate CancerPaz Nombela, Rebeca Lozano, Alvaro Aytes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2014
Circulating tumor cells: a multifunctional biomarkerTimothy A Yap, David Lorente, Aurelius Omlin, et al.
Clinical Lymphoma & Myeloma|July 11, 2007
Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remissionAntonio Rueda, David Olmos, Vicente Villareal, et al.
Gynecologic Oncology|March 25, 2014
Circulating and disseminated tumor cells in ovarian cancer: a systematic reviewNuria Romero-Laorden, David Olmos, Tanja Fehm, et al.
Cancers|September 25, 2019
Current Treatment Options for Metastatic Hormone-Sensitive Prostate CancerCarlo Cattrini, Elena Castro, Rebeca Lozano, et al.
Critical Reviews in Oncology/Hematology|January 10, 2012
Life-expectancy of patients enrolled in phase 1 clinical trials: a systematic review of published prognostic modelsAnne Ploquin, David Olmos, Charles Ferté, et al.
Pageof 13

Showing results (11-20 of 130) with videos related to

Sort By:
Pageof 13
Cancer Research|June 11, 2009
Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone drivenGerhardt Attard, Alison H M Reid, David Olmos, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 1, 2005
Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitisAntonio Rueda Domínguez, David Olmos Hidalgo, Ruth Viciana Garrido, et al.
Expert Opinion on Investigational Drugs|July 23, 2011
Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategiesTimothy A Yap, David Olmos, Lulama Rhoda Molife, et al.
Cancer Journal (Sudbury, Mass.)|June 8, 2010
Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedsideDavid Olmos, Daniel S W Tan, Robin L Jones, et al.
Cancers|March 16, 2019
BRCA2 and Other DDR Genes in Prostate CancerPaz Nombela, Rebeca Lozano, Alvaro Aytes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2014
Circulating tumor cells: a multifunctional biomarkerTimothy A Yap, David Lorente, Aurelius Omlin, et al.
Clinical Lymphoma & Myeloma|July 11, 2007
Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remissionAntonio Rueda, David Olmos, Vicente Villareal, et al.
Gynecologic Oncology|March 25, 2014
Circulating and disseminated tumor cells in ovarian cancer: a systematic reviewNuria Romero-Laorden, David Olmos, Tanja Fehm, et al.
Cancers|September 25, 2019
Current Treatment Options for Metastatic Hormone-Sensitive Prostate CancerCarlo Cattrini, Elena Castro, Rebeca Lozano, et al.
Critical Reviews in Oncology/Hematology|January 10, 2012
Life-expectancy of patients enrolled in phase 1 clinical trials: a systematic review of published prognostic modelsAnne Ploquin, David Olmos, Charles Ferté, et al.
Pageof 13